GM1 reduces infarct volume after focal cerebral ischemia.
The efficacy of monosialoganglioside GM1 treatment was evaluated in a model of experimental stroke. Cerebral ischemia was induced by permanent occlusion of left middle cerebral artery. GM1 was administered intravenously soon after the occlusion of the artery and then intramuscularly daily for 7 days. Results indicate that GM1 can reduce the extent of infarct volume and neurochemical deficits associated with the ischemic event. The protection was more evident in the cortex than in the caudate-putamen. These observations confirm and extend the evidence of the GM1 efficacy in experimental models of stroke and further support the usefulness of gangliosides in the treatment of these pathologies.
Lazzaro
A
A
FIDIA Research Laboratories, Abano Terme (PD), Italy.
Seren
M S
MS
Koga
T
T
Zanoni
R
R
Schiavo
N
N
Manev
H
H
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002421:Caudate Nucleus / Q000473:pathology; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005677:G(M1) Ganglioside / Q000627:therapeutic use*; D007546:Isoquinolines / Q000378:metabolism; D008297:Male; D011699:Putamen / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
D007546:Isoquinolines; D015102:3,4-Dihydroxyphenylacetic Acid; D005677:G(M1) Ganglioside; D002795:Choline O-Acetyltransferase; D004298:Dopamine; C037850:PK 11195